Diansong Zhou
About
Diansong Zhou is a scholar working on Oncology, Pharmacology and Pharmacology.
According to data from OpenAlex, Diansong Zhou has authored 87 papers receiving a total of 1.4k indexed citations (citations by other indexed papers that have themselves been cited), including 34 papers in Oncology, 25 papers in Pharmacology and 18 papers in Pharmacology. Recurrent topics in Diansong Zhou's work include Pharmacogenetics and Drug Metabolism (24 papers), Antibiotics Pharmacokinetics and Efficacy (12 papers) and Drug Transport and Resistance Mechanisms (11 papers). Diansong Zhou is often cited by papers focused on Pharmacogenetics and Drug Metabolism (24 papers), Antibiotics Pharmacokinetics and Efficacy (12 papers) and Drug Transport and Resistance Mechanisms (11 papers). Diansong Zhou collaborates with scholars based in United States, United Kingdom and South Korea. Diansong Zhou's co-authors include Nidal Al‐Huniti, Scott Grimm, Khanh Bui, Tommy B. Andersson, Hongmei Xu, Trevor N. Johnson, Ruifeng Liu, Jian Guo, Wangda Zhou and Shampa Das and has published in prestigious journals such as Journal of Clinical Oncology, Cancer Research and Clinical Cancer Research.
In The Last Decade
Diansong Zhou
85 papers receiving 1.3k citations
Peers
Diansong Zhou
Aaron Dane United Kingdom
Christopher Banfield United States
Dong‐Seok Yim South Korea
Wen Chyi Shyu United States
Nidal Al‐Huniti United States
Akihiro Hisaka Japan
K Rowland‐Yeo United Kingdom
MO Karlsson Sweden
Jianghong Fan United States
John Lettieri United States
Citations per year, relative to Diansong Zhou Diansong Zhou (= 1×)
peers
Aaron Dane
Countries citing papers authored by Diansong Zhou
Since
Specialization
Citations
This map shows the geographic impact of Diansong Zhou's research. It shows the number of citations coming from papers published by authors working in each country. You can also color the map by specialization and compare the number of citations received by Diansong Zhou with the expected number of citations based on a country's size and research output (numbers larger than one mean the country cites Diansong Zhou more than expected).
Fields of papers citing papers by Diansong Zhou
Since
Specialization
Physical SciencesHealth SciencesLife SciencesSocial Sciences
This network shows the impact of papers produced by Diansong Zhou. Nodes represent research fields, and links connect fields that are likely to share authors. Colored nodes show fields that tend to cite the papers produced by Diansong Zhou. The network helps show where Diansong Zhou may publish in the future.
Co-authorship network of co-authors of Diansong Zhou
This figure shows the co-authorship network connecting the top 25 collaborators of Diansong Zhou. A scholar is included among the top collaborators of Diansong Zhou based on the total number of citations received by their joint publications. Widths of edges represent the number of papers authors have co-authored together. Node borders signify the number of papers an author published with Diansong Zhou. Diansong Zhou is excluded from the visualization to improve readability, since they are connected to all nodes in the network.
All Works
1.
Yang, Jincheng, Aarti Sawant‐Basak, A. Todd, et al.. (2025). Population Pharmacokinetics and Exposure‐Response Analysis of First‐Line Osimertinib Plus Chemotherapy in Patients with EGFR ‐Mutated Advanced NSCLC . Clinical Pharmacology & Therapeutics. 118(5). 1110–1121.
2.
Fernández‐Teruel, Carlos, Marie Cullberg, Ignacio Ferreira González, et al.. (2025). Population Pharmacokinetics and Exposure–Response Analyses for Capivasertib in Combination With Fulvestrant in Patients With Breast Cancer. Clinical and Translational Science. 18(7). e70286–e70286.
3.
Zhou, Diansong, et al.. (2025). Minor Contribution of UGT1A1 Inhibition to Atazanavir‐Related Bilirubin Elevation Supported by Conservative PBPK Modeling and Clinical Data. Clinical Pharmacology & Therapeutics. 119(3). 583–586.
4.
Hong, Ying, Naoyuki Tajima, Hong Zebger‐Gong, et al.. (2025). Population Pharmacokinetic Analysis of Datopotamab Deruxtecan (Dato‐ DXd ), a TROP2 ‐Directed Antibody‐Drug Conjugate, in Patients With Advanced Solid Tumors. CPT Pharmacometrics & Systems Pharmacology. 14(12). 2149–2160.
5.
Fernández‐Teruel, Carlos, Marie Cullberg, Cath Eberlein, Simon T. Barry, & Diansong Zhou. (2024). Population Pharmacokinetics of Capivasertib in Patients with Advanced or Metastatic Solid Tumours. Clinical Pharmacokinetics. 63(8). 1191–1204.
6.
Sharma, Pradeep, David W. Cheung, Weifeng Tang, et al.. (2024). Inhibition of OATP1B1 /3 Rather Than UGT1A1 May Be the Major Cause of the Bilirubin Elevation After Atazanavir Administration. Clinical Pharmacology & Therapeutics. 118(2). 497–509.
7.
Armstrong, Andrew J., Noel W. Clarke, Giuseppe Procopio, et al.. (2023). Olaparib plus Abiraterone for Metastatic Castration-resistant Prostate Cancer: Pharmacokinetics Data from the PROpel Trial. European Urology Oncology. 7(2). 292–296.
8.
He, Zhijian, Xuyang Song, Cecil Chen, et al.. (2023). Population Pharmacokinetics and Exposure–Response Analysis of Tremelimumab 300 mg Single Dose Combined with Durvalumab 1500 mg Q4W (STRIDE) in Patients with Unresectable Hepatocellular Carcinoma. The Journal of Clinical Pharmacology. 63(11). 1221–1231.
9.
He, Zhijian, Vincent Duval, António Gonçalves, et al.. (2023). Population Pharmacokinetics and Exposure–Response Analysis for the CTLA‐4 Inhibitor Tremelimumab in Metastatic NSCLC Patients in the Phase III POSEIDON Study. Clinical Pharmacology & Therapeutics. 114(6). 1375–1386.
10.
Song, Xuyang, Robin Kate Kelley, Michelle Green, et al.. (2023). Modeling of Proliferating CD4 and CD8 T‐Cell Changes to Tremelimumab Exposure in Patients with Unresectable Hepatocellular Carcinoma. Clinical Pharmacology & Therapeutics. 114(4). 874–882.
11.
Song, Xuyang, Robin Kate Kelley, Anis A. Khan, et al.. (2022). Exposure-Response Analyses of Tremelimumab Monotherapy or in Combination with Durvalumab in Patients with Unresectable Hepatocellular Carcinoma. Clinical Cancer Research. 29(4). 754–763.
12.
Zhou, Diansong, Hua Wei, Jean Cheung, et al.. (2022). Acalabrutinib CYP3A‐mediated drug–drug interactions: Clinical evaluations and physiologically based pharmacokinetic modelling to inform dose adjustment strategy. British Journal of Clinical Pharmacology. 88(8). 3716–3729.
13.
Reddy, Venkatesh Pilla, Adrian J. Fretland, Diansong Zhou, et al.. (2021). Mechanistic physiology-based pharmacokinetic modeling to elucidate vincristine-induced peripheral neuropathy following treatment with novel kinase inhibitors. Cancer Chemotherapy and Pharmacology. 88(3). 451–464.
14.
Schalkwijk, Stein, Li Zhou, Lokesh Jain, et al.. (2021). Population pharmacokinetics and exposure–response of selumetinib and its N‐desmethyl metabolite in pediatric patients with neurofibromatosis type 1 and inoperable plexiform neurofibromas. Cancer Chemotherapy and Pharmacology. 88(2). 189–202.
15.
Ishikawa, Kensuke, et al.. (2020). Physiologically Based Pharmacokinetic Modelling of Glycopyrronium in Patients With Renal Impairment. Journal of Pharmaceutical Sciences. 110(1). 438–445.
16.
Agbo, Felix, Khanh Bui, & Diansong Zhou. (2017). Population pharmacokinetic analysis of lanicemine (AZD6765), an NMDA channel blocker, in healthy subjects and patients with major depressive disorder. Journal of Clinical Pharmacy and Therapeutics. 42(5). 539–546.
17.
Bui, Khanh, Diansong Zhou, Felix Agbo, & Jian Guo. (2015). Effect of multiple intravenous doses of lanicemine (AZD6765) on the pharmacokinetics of midazolam in healthy subjects. The Journal of Clinical Pharmacology. 55(9). 1024–1030.
18.
Guo, Jian, Chungang Gu, Diansong Zhou, et al.. (2011). In Vitro and In Vivo Metabolism of a Selective δ-Opioid Receptor. Drug Metabolism and Disposition. 39(10). 1883–1894.
19.
Guo, Jian, Diansong Zhou, & Scott Grimm. (2011). Liquid chromatography–tandem mass spectrometry method for measurement of nicotine N-glucuronide: A marker for human UGT2B10 inhibition. Journal of Pharmaceutical and Biomedical Analysis. 55(5). 964–971.
20.
Zhou, Diansong, et al.. (1998). Single‐ and Multiple‐Dose Pharmacokinetic Comparison of a Sustained‐Release Tablet and Conventional Tablets of Naproxen in Healthy Volunteers. The Journal of Clinical Pharmacology. 38(7). 625–629.
Rankless uses publication and citation data sourced from OpenAlex, an open and comprehensive bibliographic database. While OpenAlex provides broad and valuable coverage of the global research landscape, it—like all bibliographic datasets—has inherent limitations. These include incomplete records, variations in author disambiguation, differences in journal indexing, and delays in data updates. As a result, some metrics and network relationships displayed in Rankless may not fully capture the entirety of a scholar's output or impact.
Explore authors with similar magnitude of impact
Breakdown of academic impact, for papers by Aaron Dane Breakdown of academic impact, for papers by Christopher Banfield Breakdown of academic impact, for papers by Dong‐Seok Yim Breakdown of academic impact, for papers by Wen Chyi Shyu Breakdown of academic impact, for papers by Nidal Al‐Huniti Breakdown of academic impact, for papers by Akihiro Hisaka Breakdown of academic impact, for papers by K Rowland‐Yeo Breakdown of academic impact, for papers by MO Karlsson Breakdown of academic impact, for papers by Jianghong Fan Breakdown of academic impact, for papers by John Lettieri